
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics is compelling fundamentally because PrimeC has repeatedly shown a multi-target mechanism that aligns with the shared biology of ALS, AD, and PD, including reductions in TDP-43, neuroinflammation, and iron dysregulation, while preclinical and biomarker work suggests synergistic activity from ciprofloxacin plus celecoxib rather than simple repurposing. Its clinical package is stronger than a typical early biotech, with Phase 2b PARADIGM in 68 patients showing favorable tolerability, a 65% reduction in death risk (HR=0.35, p=0.004), and median survival of 36.3 months versus 21.4 months, plus supportive Phase 2a and RoAD signals. The upside is further reinforced by a differentiated regulatory path, including FDA-cleared Phase 3 PARAGON and a planned Health Canada NDS in late 4Q26, though limited cash and financing risk remain key valuation overhangs.
Bears say
NeuroSense Therapeutics is facing a weakened investment case because its core thesis depends on PrimeC, yet key milestones have slipped to March 2027 for the Canadian NDS submission and mid-2027 for Phase 3 initiation, increasing execution uncertainty. The company’s financial position is also fragile, with 1H26 EPS of ($2.06) after a 1:20 reverse split and only $0.2 million in cash at the end of 1H26, while continued development is contingent on securing additional funding. In addition, two live Nasdaq deficiencies, including a sub-$1.00 bid price and MVSL below $35 million with a September 29, 2026 cure deadline, raise delisting risk that could further impair financing and clinical progress.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares